The U.S. Patent & Trademark Office publishes same filing-to-registration timelines for applications filed based on different bases.
Today’s timeline shows a sample timeline for a Section 1(b) intent-to-use application:
For the full-sized version of the flowchart, please click here. We hope this information is useful.
If you have any questions or concerns, please do not hesitate to contact us.
On Tuesday, the FDA announced that it approved the first flu vaccine comprising animal cell cultures. The vaccine, to be marketed under the trademark FLUCELVAX, is a Novartis product. FLUCELVAX will be manufactured in Novartis’ brand new North Carolina plant.
The vaccine is produced with virus strains that are grown in animal cell cultures derived from mammals instead of in chicken eggs. Similar cell culture technology has long been used to produce other types of vaccines, FDA said.
FDA press release here.